224 related articles for article (PubMed ID: 29789417)
1. Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation.
Löffler MW; Kowalewski DJ; Backert L; Bernhardt J; Adam P; Schuster H; Dengler F; Backes D; Kopp HG; Beckert S; Wagner S; Königsrainer I; Kohlbacher O; Kanz L; Königsrainer A; Rammensee HG; Stevanović S; Haen SP
Cancer Res; 2018 Aug; 78(16):4627-4641. PubMed ID: 29789417
[TBL] [Abstract][Full Text] [Related]
2. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
[TBL] [Abstract][Full Text] [Related]
3. Proteogenomic discovery of cancer antigens: Neoantigens and beyond.
Kanaseki T; Tokita S; Torigoe T
Pathol Int; 2019 Sep; 69(9):511-518. PubMed ID: 31397525
[TBL] [Abstract][Full Text] [Related]
4. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy.
Marcu A; Bichmann L; Kuchenbecker L; Kowalewski DJ; Freudenmann LK; Backert L; Mühlenbruch L; Szolek A; Lübke M; Wagner P; Engler T; Matovina S; Wang J; Hauri-Hohl M; Martin R; Kapolou K; Walz JS; Velz J; Moch H; Regli L; Silginer M; Weller M; Löffler MW; Erhard F; Schlosser A; Kohlbacher O; Stevanović S; Rammensee HG; Neidert MC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858848
[TBL] [Abstract][Full Text] [Related]
5. The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Mühlenbruch L; Abou-Kors T; Dubbelaar ML; Bichmann L; Kohlbacher O; Bens M; Thomas J; Ezić J; Kraus JM; Kestler HA; von Witzleben A; Mytilineos J; Fürst D; Engelhardt D; Doescher J; Greve J; Schuler PJ; Theodoraki MN; Brunner C; Hoffmann TK; Rammensee HG; Walz JS; Laban S
Br J Cancer; 2023 May; 128(9):1777-1787. PubMed ID: 36823366
[TBL] [Abstract][Full Text] [Related]
6. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
7. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
[TBL] [Abstract][Full Text] [Related]
8. A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Löffler MW; Nussbaum B; Jäger G; Jurmeister PS; Budczies J; Pereira PL; Clasen S; Kowalewski DJ; Mühlenbruch L; Königsrainer I; Beckert S; Ladurner R; Wagner S; Bullinger F; Gross TH; Schroeder C; Sipos B; Königsrainer A; Stevanović S; Denkert C; Rammensee HG; Gouttefangeas C; Haen SP
Front Immunol; 2019; 10():2526. PubMed ID: 31803175
[No Abstract] [Full Text] [Related]
9. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer.
Lee HJ; Hong CY; Jin CJ; Kim MH; Lee YK; Nguyen-Pham TN; Lee H; Park BC; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Mar; 9(2):175-83. PubMed ID: 22231555
[TBL] [Abstract][Full Text] [Related]
10. Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.
Kumar P; Boyne C; Brown S; Qureshi A; Thorpe P; Synowsky SA; Shirran S; Powis SJ
Immunology; 2022 Jun; 166(2):249-264. PubMed ID: 35318648
[TBL] [Abstract][Full Text] [Related]
11. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
12. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.
Bilich T; Nelde A; Bichmann L; Roerden M; Salih HR; Kowalewski DJ; Schuster H; Tsou CC; Marcu A; Neidert MC; Lübke M; Rieth J; Schemionek M; Brümmendorf TH; Vucinic V; Niederwieser D; Bauer J; Märklin M; Peper JK; Klein R; Kohlbacher O; Kanz L; Rammensee HG; Stevanović S; Walz JS
Blood; 2019 Feb; 133(6):550-565. PubMed ID: 30530751
[TBL] [Abstract][Full Text] [Related]
13. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
Kowalewski DJ; Schuster H; Backert L; Berlin C; Kahn S; Kanz L; Salih HR; Rammensee HG; Stevanovic S; Stickel JS
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):E166-75. PubMed ID: 25548167
[TBL] [Abstract][Full Text] [Related]
14. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
15. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Roerden M; Nelde A; Walz JS
Front Immunol; 2019; 10():3004. PubMed ID: 31921218
[TBL] [Abstract][Full Text] [Related]
16. The human leukocyte antigen-presented ligandome of B lymphocytes.
Hassan C; Kester MG; de Ru AH; Hombrink P; Drijfhout JW; Nijveen H; Leunissen JA; Heemskerk MH; Falkenburg JH; van Veelen PA
Mol Cell Proteomics; 2013 Jul; 12(7):1829-43. PubMed ID: 23481700
[TBL] [Abstract][Full Text] [Related]
17. Sampling From the Proteome to the Human Leukocyte Antigen-DR (HLA-DR) Ligandome Proceeds Via High Specificity.
Mommen GP; Marino F; Meiring HD; Poelen MC; van Gaans-van den Brink JA; Mohammed S; Heck AJ; van Els CA
Mol Cell Proteomics; 2016 Apr; 15(4):1412-23. PubMed ID: 26764012
[TBL] [Abstract][Full Text] [Related]
18. Acid Stripping after Infection Improves the Detection of Viral HLA Class I Natural Ligands Identified by Mass Spectrometry.
Lorente E; Marcilla M; de la Sota PG; Quijada-Freire A; Mir C; López D
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638844
[TBL] [Abstract][Full Text] [Related]
19. Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma.
de Beijer MTA; Bezstarosti K; Luijten R; Doff WAS; Boor PPC; Pieterman RFA; Bouzid R; Biesta PJ; Ijzermans JNM; Doukas M; de Man RA; Woltman AM; Demmers JAA; Buschow SI
JHEP Rep; 2022 Nov; 4(11):100576. PubMed ID: 36185575
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
